NCT01116843View on ClinicalTrials.gov

Study to Assess Biomarkers in Patients With Resectable Oral Cavity Cancer Randomized to Receive Preoperative Treatment

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

February 29, 2012

Study Completion Date

February 28, 2014

Conditions
Oral Cavity Cancer
Interventions
DRUG

PF-00299804

PF-00299804 or Placebo given pre-operatively for 7 to 11 days depending on surgery schedule.

Trial Locations (1)

M5G 2M9

Princess Margaret Hospital, Toronto

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

University Health Network, Toronto

OTHER